Trexquant Investment LP Esperion Therapeutics, Inc. Transaction History

Trexquant Investment LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $248,302 - $370,402	45,560 New	45,560 $305,000
Q2 2021 Aug 12, 2021	SELL	$19.4 - $28.71 $306,655 - $453,818	-15,807 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$25.12 - $36.89 $397,071 - $583,120	15,807 New	15,807 $443,000
Q3 2020 Nov 06, 2020	SELL	$31.18 - $52.71 $501,748 - $848,209	-16,092 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$30.04 - $51.31 $483,403 - $825,680	16,092 New	16,092 $826,000
Q3 2019 Nov 08, 2019	SELL	$34.47 - $47.53 $709,013 - $977,644	-20,569 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$40.1 - $52.33 $247,256 - $322,666	6,166 Added 42.81%	20,569 $957,000
Q1 2019 May 13, 2019	BUY	$40.11 - $53.57 $269,619 - $360,097	6,722 Added 87.51%	14,403 $578,000
Q4 2018 Feb 13, 2019	SELL	$36.99 - $59.11 $423,091 - $676,100	-11,438 Reduced 59.83%	7,681 $353,000
Q3 2018 Nov 09, 2018	BUY	$40.74 - $51.41 $778,908 - $982,907	19,119 New	19,119 $848,000
Q4 2017 Feb 09, 2018	SELL	$43.47 - $67.43 $721,210 - $1.12 Million	-16,591 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$43.8 - $52.77 $726,685 - $875,507	16,591	16,591 $832,000

209

129M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $140M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.